Healthy Skepticism Library
Items published during the years 1990 to 1999
There are 2362 items in the Healthy Skepticism Library that were published during the years 1990 to 1999.
Page 16 of 24 pages ‹ First < 14 15 16 17 18 > Last ›
HSL20516
Haramburu F, Miremont G, Chaslerie A, Bégaud B, Dangoumau J
Efficiency of medical journals for pharmacovigilance
The Lancet 1993 Apr 17; 341:(8851):1030 - 1031
http://www.thelancet.com/journals/lancet/article/PII0140-6736%2893%2991125-6/fulltext
HSL9384
Levy SB.
Confronting multidrug resistance: A role for each of us
JAMA 1993 Apr 14; 269:1840-1842
HSL5548
Arnst C.
Is good marketing bad medicine? Why costlier, riskier hypertension drugs are best-sellers
Business Week 1993 Apr 13
HSL20545
Busetto D
Gangliosides regulation debacle
The Lancet 1993 Apr 10; 341:949
HSL5165
Lober CW.
Ethics in pharmaceutical advertising.
Dermatol Clin 1993 Apr 01; 11:(2):285-8
HSL5015
Islam AF.
Improving drug utilization: what about the 'KAP' gap?
Trop Doct 1993 Apr; 23:(2):89-90
HSL5545
Re: the promotion of Junifen (ibuprofen)
1993 Apr
HSL5546
Summary of outcomes for topics commenced April 1991 to October 1991
MaLAM International News 1993 Apr
HSL9325
Price is wrong
NARD J 1993 Apr; 115:18-21
HSL9327
Dundass H.
Getting the act together
Can Pharm J 1993 Apr; 126:132-133, 135, 138, 141
HSL9346
Miller PJ.
1992 In review: why aren't marketers smiling?
Medical Marketing and Media 1993 Apr; 28:12-14, 16, 18-26
HSL9378
Simonsen LL.
What are pharmacists dispensing most often?
Pharmacy Times 1993 Apr; 59:29-30, 32, 34, 36, 39-40, 42-4
HSL20534
Ragg M
Doctored facts for GPs
The Bulletin 1993 Mar 3016-17
HSL5539
PAAB annual & general meetings: highlights
PMAC Bulletin 1993 Mar 15
HSL9345
Xenakis A.
DTC advertising: don't bypass pharmacists
Drug Store News for the Pharmacists 1993 Mar 15; 3:51
HSL19893
Harrington R
Drug advertisements
BMJ 1993 Mar 13; 306:721
HSL4678
Brotzman GL, Mark DH.
The effect on resident attitudes of regulatory policies regarding pharmaceutical representative activities.
J Gen Intern Med 1993 Mar; 8:(3):130-4
HSL5536
Government finds industry promotion code works well in Australia
Health Horizons 1993 Mar
HSL5537
Re: the promotion of Diodoquin (iodoquinol) and Lomotil (diphenoxylate/atropine)
1993 Mar
HSL5538
Tobias G.
Regulation of drug advertising—a violation of free speech?
Scrip Magazine 1993 Mar
HSL9379
Clinton team works with drug companies to expand access, restrict costs.
Am J Hosp Pharm. 1993 Mar; 50:(3):388, 391
HSL20522
Greenberg DS
Washington Perspective
Lancet 1993 Feb 27; 341:(8714):556 - 557
http://day.thelancet.com/journals/lancet/article/PII0140-6736%2890%2992101-M/fulltext
HSL20544
Kondro W
Drug assessment
The Lancet 1993 Feb 27; 341:(8844):550 - 551
http://www.lancet.com/journals/lancet/article/PII0140-6736%2893%2990301-V/fulltext
HSL5535
Marketing code amendments approved
PMAC Bulletin 1993 Feb 26
HSL4669
Arkinstall WW.
Physicians and the pharmaceutical industry.
CMAJ 1993 Feb 15; 148:(4):485
HSL4689
Dingle B.
Physicians and the pharmaceutical industry.
CMAJ 1993 Feb 15; 148:(4):485-6
HSL4688
Dieppe PA, Frankel SJ, Toth B.
Is research into the treatment of osteoarthritis with non-steroidal anti-inflammatory drugs misdirected?
Lancet 1993 Feb 6; 341:(8841):353-4
HSL5021
Kingswell RS.
Consensus conferences as drug promotion.
Lancet 1993 Feb 6; 341:(8841):368
HSL5528
Winder T.
Consensus conferences as drug promotion.
Lancet 1993 Feb 6; 341:(8841):368-9
HSL5533
MaLAM Letter follow up—antidiarrhoeals
MaLAM International Newsletter 1993 Feb
HSL5534
Drug labeling in developing countries
1993 Feb
HSL9336
Disgrace at the border
NARD J 1993 Feb; 115:22-27
HSL9374
Dichter E.
Managing the drug benefit for cost and quality advantage
AAPPO Journal 1993 Feb-Mar; 3:37, 41
HSL9377
Gosselin RA.
Pharmacy/industry collaborate to improve quality of public programs
Pharmacy Times 1993 Feb; 59:73-75
HSL9383
Collins DE.
Rx and OTC: why neither will ever be the same
Medical Marketing and Media 1993 Feb; 28:20-24, 26
HSL9385
PMA recommends policy on patient confidentiality in prescription databases
American Journal of Hospital Pharmacy 1993 Feb; 50:208
HSL9332
Gannon K.
OTCs-shelf busters: analyzing nonprescription drug trends
Drug Top 1993 Jan 25; 137:34-36, 38-39, 41
HSL5530
Weber J, Carey J.
Drug ads: A prescription for controversy
Business Week 1993 Jan 1858-59
HSL9337
Troy M.
FDA's new OTC advisory committee has hands full with safety issues
Drug Store News for the Pharmacists 1993 Jan 18; 3:16
HSL20405
Sullivan P
CMA guidelines concerning relationship of MDs and drug industry to be revised, board told
CMAJ 1993 Jan 15; 148:(2):273–275
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1490398/
HSL4679
Newman TB.
Possibly disappointing results of treatment with gemfibrozil.
N Engl J Med 1993 Jan 14; 328:(2):139-40
HSL5526
Whyte J.
Direct consumer advertising of prescription drugs.
JAMA 1993 Jan 6; 269:(1):146,
HSL1773
Miller LG, Blum A.
Physician awareness of prescription drug costs: a missing element of drug advertising and promotion.
J Fam Pract 1993 Jan; 36:(1):33-6
HSL5514
Stephens MD.
Marketing aspects of company-sponsored postmarketing surveillance studies.
Drug Saf 1993 Jan; 8:(1):1-8
HSL5521
Vinson DC, McCandless B, Hosokawa MC.
Medical students' attitudes toward pharmaceutical marketing: possibilities for change.
Fam Med 1993 Jan; 25:(1):31-3
HSL5531
MaLAM Letter follow up—Bayer aspirin and nimodipine
MaLAM International Newsletter 1993 Jan1-2
HSL5532
Re: the promotion of Mucosolvan (ambroxol)
1993 Jan
HSL9387
Congress compromises on Medicaid drug pricing; 'best price' excludes VA, others.
Am J Hosp Pharm. 1993 Jan; 50:(1):16, 19
HSL9393
FDA user fees approved.
Clin Pharm. 1993 Jan; 12:(1):3
HSL9394
FDA proposes more stringent pediatric-use labeling of prescription drug products.
Clin Pharm. 1993 Jan; 12:(1):6
HSL13286
Keller KL.
Conceptualizing, Measuring, Managing Customer-Based Brand Equity
Journal of Marketing 1993 Jan; 57:(1):1-22
http://www.marketingpower.com/content17640.php
HSL1825
Ranwella S.
Sri Lankan students campaign for rational medicine: the story of SIRHA.
Essent Drugs Monit 1993; (16):10
HSL4654
Consultants in Pharmaceutical Media, Inc.
AD/Rx: 1993 annual analysis
Kulpsville, Pennsylvania: Consultants in Pharmaceutical Media, Inc. 1993
HSL4655
HAI international meeting report: Drug promotion and independent drug information
Amsterdam: Health Action International 1993
HSL4656
Ethics case study: should drug makers support continuing medical education
American College of Physicians Observer 1993; 13:(6):1,12-13
HSL4657
World Health Organization
FDA acts against misleading marketing of osalazine
Essential Drugs Monitor 1993; (16):3
HSL4658
HAI international meeting report: Open forum: promoting health or pushing drugs
Geneva: Health Action International 1993
HSL4660
Sponsored symposia: science or veiled promotion?
WHO Drug Information 1993; 7:26-27
HSL4661
Ahmad SR.
FDA and olsalazine
Lancet 1993; 342:487
HSL4662
Ahmad SR.
Misleading advertising of Zantac
Lancet 1993; 341:748
HSL4663
Alden , Errol R., Dow J
Advertising in Pediatrics
Pediatrics 1993; 92:(4):610
HSL4664
Alperstein N, Peyrot M
Consumer awareness of prescription drug advertising
Journal of Advertising Research 1993; 33:(4):50-56
HSL4665
American Business Press/Advertising Research Foundation
Product growth: how can it be achieved in an era of tighter resources? The ARF/ABP pharmaceutical study
New York: American Business Press 1993
HSL4670
Arnold , R. B.
Self-regulation of the promotion and marketing of prescription medicines
Drugs Made in Germany 1993; 36:(3):75-78
HSL4671
Bader , Jean-michel .
Confusion over drug-industry gifts
Lancet 1993; 341:750
HSL4672
Bentley , Marjorie .
Drug advertising requires special rules for a special marke
CMAJ 1993; 149:209-210, 212
HSL4673
Bero L, Galbraith A, Rennie D
Publication of sponsored symposiums in medical journals
New England Journal of Medicine 1993; 328:1197-1198
HSL4674
Boer , A .
Pharmaceutical advertising in medical journals
JAMA 1993; 268:147-148, 151
HSL4675
Bonfiglio , T .
What’s in a name? The marketing of pharmaceutics
JAMA 1993; 268:148
HSL4676
Braithwaite , J .
Transnational regulation of the pharmaceutical industry
Annals of the American Academy of Political and Social Science 1993; 525:12-30
HSL4677
Brodie-brown , W. F.
Pharmaceutical ads under editorial control: is it necessary. Response
Canadian Medical Association Journal 1993; 39:1325
HSL4680
Cavalli , F.
Our policy regarding supplements of sponsored research
Annals of Oncology 1993; 4:99
HSL4684
Collier J, Fox R.
WHO seeks ways to improve control of drug promotion
Lancet 1993; 341:1017
HSL4685
Davis , P .
The cost of CME: who pays?
Canadian Journal of CME 1993; 5:(9):1-2
HSL4687
Dickstein , H .
Changing over-the-counter drugs while retaining the brand name
Annals of Internal Medicine 1993; 118:988
HSL4691
Dixon , T .
Physicians and drug companies interact
Canadian Family Physician 1993; 39:1882
HSL4692
Drake D.
Making medicine making money
Kansas City: Andrews and McMeel 1993
HSL4693
Editor .
Drug advertisements
BMJ 1993; 306:720
HSL4698
Frankel D.
Drug labelling in developing countries
Lancet 1993; 341:1469
HSL4702
Hawkins J, Aber C, .
Women in advertisements in medical journals
Sex Roles 1993; 28:233-242
HSL4703
Herxheimer A, Lundborg CS, Westerholm B.
Advertisements for medicines in leading medical journals in 18 countries: a 12-month survey of information content and standards.
Int J Health Serv 1993; 23:(1):161-72
HSL5010
Houle G.
CME—where are we going?
Canadian Journal of CME 1993; 5:(1):1
HSL5011
Howie JG.
Breaking down drug company barriers
BMJ 1993; 307:384
HSL5013
Huston P.
Doctors want more industry-sponsored meetings
Medical Marketing & Media 1993; 28:(3):48-50, 52-53
HSL5016
Jablonsky G.
Physicians and the pharmaceutical industry
Canadian Medical Association Journal 1993; 148:486
HSL5023
Krause J, Nour Eldin.
Ethical criteria and pharmaceutical advertising
Drugs made in Germany 1993; 36:(3):78-90
HSL5024
La Puma, Stocking CB, Rhoades CM.
Should disclosure of MD remuneration be part of informed consent to research on new drugs?
Clinical Research 1993; 41:(2):578
HSL5025
Drug promotion: stealth, wealth, and safety
The Lancet 1993; 341:1507-1508
HSL5026
Ghost with a chance in publishing undergrowth
Lancet 1993; 342:1498-1499
HSL5027
Leppard W, Ogletree SM, Wallen E.
Gender stereotyping in medical advertising: much ado about something?
Sex Roles 1993; 29:829-838
HSL5166
Makkonen K.
Problems in distribution of scientific knowledge: intrauterine contraceptive devices and drug catalogs.
Int J Health Serv 1993; 23:(1):173-83
HSL5173
Michalko K, Gibbs B.
Pharmaceutical representative committee
Canadian Journal of Hospital Pharmacy 1993; 46:84
HSL5239
Millstein LG.
Deceptive x-ray films in an advertisement
New England Journal of Medicine 1993; 329:1207
HSL5241
Morrissy J.
Pharmaceutical ads under editorial control: is it necessary?
Canadian Family Physician 1993; 39:1325
HSL5243
Noble RC.
Physicians and the pharmaceutical industry: an alliance with unhealthy aspects.
Perspect Biol Med 1993 Spr; 36:(3):376-94
HSL5245
Paul R.
Labels for nonprescription medications
New England Journal of Medicine 1993; 329:281
HSL5247
Penick TM.
New trends in direct-to-consumer advertising: The Actigall campaign
Journal of Pharmaceutical Marketing & Management 1993; 7:(3):95-107
HSL5248
Ragg M.
MaLAM and Augmentin
Lancet 1993; 342:487
HSL5251
Regush N.
A case of mistaken identity: Toradol for pain relief
1993
HSL5254
Rouse CF.
Single-drug therapy for hypertension in men
New England Journal of Medicine 1993; 329:1045
Page 16 of 24 pages ‹ First < 14 15 16 17 18 > Last ›
